

Blue Cross Blue Shield of Vermont and The Vermont Health Plan Prior Authorization for Copaxone (Glatiramer acetate)

BCBSVT and TVHP Fax # (888)-255-1006

If approval criteria are met BCBSVT/TVHP will authorize coverage of Copaxone (Glatiramer acetate). Thank you for your assistance.

PLEASE COMPLETE THE FOLLOWING SECTIONS:

Date of Request _____ Patient Name: _____
 Member ID#: _____ Date of Birth: _____
 Provider Name: _____ Provider Phone: _____
 Provider Fax: _____ PCP Name: _____

INDICATIONS FOR USE	<u>YES</u>	<u>NO</u>
Initial therapy <input type="checkbox"/> Renewal of existing therapy <input type="checkbox"/> Answer question 2 and 5		
1. Patient is diagnosed with clinically definite multiple sclerosis (relapsing-remitting or relapsing-progressive) by a neurologist as defined below: If Yes, continue to 1a	<input type="checkbox"/>	<input type="checkbox"/>
a) Two occurrences of a symptom(s) or neurologic dysfunction each lasting a minimum of 24 hours with a symptom-free period of at least one month between occurrences and evidence of two separate signs of neurological dysfunction on clinical exam; or	<input type="checkbox"/>	<input type="checkbox"/>
b) Occurrences of a symptom(s) of neurologic dysfunction each lasting a minimum of 24 hours with a symptom-free period of at least one month between occurrences, and evidence of one sign of neurological dysfunction on clinical exam and supporting evidence of another separate lesion.	<input type="checkbox"/>	<input type="checkbox"/>
2. Classification of Disease (check one): <input type="checkbox"/> relapsing/remitting <input type="checkbox"/> relapsing/progressing <input type="checkbox"/> chronic/progressive		
3. Patient currently has active MS, defined as at least two acute exacerbations within the previous two years.	<input type="checkbox"/>	<input type="checkbox"/>
4. Document dates and nature of exacerbations during the past two years:		
5. General description of functional status: (e.g. Is member able to fulfill activities of daily living without assistance? Is member able to ambulate?)		
6. Does patient have a hypersensitivity to mannitol?	<input type="checkbox"/>	<input type="checkbox"/>
7. Will Prescription be dispensed at (circle one): Provider Office Network Pharmacy		

MEDICATION WILL ONLY BE DISPENSED IN 30 DAY SUPPLIES

Dose: _____ Frequency: _____ Duration of Therapy: _____

PRESCRIBER SIGNATURE _____ DATE _____

By signing above, the prescriber confirms all information provided is accurate and verifiable via member records.



**BlueCross BlueShield
of Vermont**
Independent Licenses of the Blue Cross and Blue Shield Association.

